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        Introduction 
  The active vitamin D metabolite 1,25-dihydroxyvitamin D  3  
(1,25(OH)  2 D 3  ) is a pleiotropic hormone with broad regulatory ef-
fects on the proliferation, differentiation, and survival of many cell 
types  ( Ord ó  ñ ez-Mor á n  et  al.,  2005 ;   Campbell  and Adorini,  2006 ). 
On the basis of extensive epidemiological and preclinical evidence 
(  Grant and Garland, 2004  ;   Giovannucci et al., 2006  ;   Wu et al., 
2007 ),  1,25(OH) 2 D 3   and several less calcemic derivatives are 
currently under clinical study alone or in combination as potential 
agents against colorectal cancer and other neoplasias (  Schwartz 
et al., 2005  ;   Agoston et al., 2006  ;   Deeb et al., 2007  ). 1,25(OH)  2 D 3  
inhibits the proliferation and promotes the differentiation to a nor-
mal adhesive epithelial phenotype of human colon cancer cells 
through the transcriptional activation of   CDH1   gene  encoding 
E-cadherin and the antagonism of the Wnt –   -catenin signaling path-
way (  P  á  lmer et al., 2001  ), which is aberrantly activated in   >  80% of 
human colorectal cancers. E-cadherin is the critical component of 
the adherens junctions, the intercellular structure needed for the 
correct formation of compact epithelial layers (  P  é  rez-Moreno 
et al., 2003  ). Loss of E-cadherin expression is a requisite for cell 
deadhesion and migration during the epithelial to mesenchymal 
T
he active vitamin D metabolite 1,25-dihydroxy-
vitamin D  3   (1,25(OH)  2  D  3  ) inhibits proliferation and 
promotes differentiation of colon cancer cells through 
the activation of vitamin D receptor (VDR), a transcription 
factor of the nuclear receptor superfamily. Additionally, 
1,25(OH)  2  D  3   has several nongenomic effects of uncertain 
relevance. We show that 1,25(OH)  2  D  3   induces a tran-
scription-independent Ca 
2+   inﬂ  ux and activation of RhoA  –
  Rho-associated coiled kinase (ROCK). This requires VDR 
and is followed by activation of the p38 mitogen-activated 
protein kinase (p38MAPK) and mitogen- and stress-  activated 
kinase 1 (MSK1). As shown by the use of chemical inhibi-
tors, dominant-negative mutants and small interfering 
RNA, RhoA  –  ROCK, and p38MAPK-MSK1 activation is 
necessary for the induction of   CDH1  /E-cadherin,   CYP24  , 
and other genes and of an adhesive phenotype by 
1,25(OH)  2  D  3  . RhoA  –  ROCK and MSK1 are also required 
for the inhibition of Wnt  –      -catenin pathway and cell 
proliferation. Thus, the action of 1,25(OH)  2  D  3   on colon 
carcinoma cells depends on the dual action of VDR as 
a transcription factor and a nongenomic activator of 
RhoA  –  ROCK and p38MAPK-MSK1.
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eration, differentiation, survival, invasiveness, and metastatic 
potential and also in basic cell functions (  P  á  lmer et al., 2003  ). 
Additionally, rapid, transcription-independent (nongenomic) 
actions of 1,25(OH)  2 D 3  on cytosolic kinases, phosphatases, phos-
pholipases, or membrane ion channels have been described, 
although their role and relevance for the anticancer action of 
1,25(OH)  2 D 3   and their relation to the genomic effects are poorly 
understood (  Losel et al., 2003  ;   Norman et al., 2004  ). 
  Here we demonstrate that transcriptional activation by 
1,25(OH)  2 D 3   of E-cadherin and   CYP24  , which is its most re-
sponsive target gene that encodes the 1,25(OH)  2 D 3   24-hydroxy-
lase (  Vaisanen et al., 2005  ), is mediated by a Ca 
2+ -dependent 
transient activation of the small GTPase RhoA and its immedi-
ate effector Rho-associated coiled kinase (ROCK). Thereafter, 
1,25(OH)  2 D 3   activates the p38MAPK and its target the mitogen- 
and stress-activated kinase 1 (MSK1). Activity of these kinases 
is required for induction of   CDH1  /E-cadherin transcription and 
the acquisition of an adhesive epithelial phenotype and for the 
inhibition of    -catenin – TCF  transcriptional  activity.  Our  results 
indicate that the gene regulatory activity of 1,25(OH)  2 D 3   and its 
antiproliferative and prodifferentiation effects depend on the 
early, nongenomic increase in cytosolic Ca 
2+   concentration 
([Ca 
2+ ] cyt  ) and the subsequent activation of RhoA  –  ROCK and 
p38MAPK-MSK1. 
  Results 
  1,25(OH)  2  D  3   induces Ca 
2+   inﬂ  ux and 
activates RhoA 
  As the Rho family of GTPases are key regulators of cytoskele-
ton dynamics and cell adhesion and migration (  Burridge and 
transition and is common in carcinomas (  Takeichi, 1993  ). Activa-
tion of the Wnt  –      -catenin pathway by mutation of intracellular 
components such as   APC ,   AXIN  , or   CTNNB1 /   -catenin genes or 
epigenetic alteration of Wnt inhibitors such as   DKK-1 ,   SFRPs ,  or 
  WIF  is the initial step in colorectal tumorigenesis ( van de Wetering 
et al., 2002  ;   Sancho et al., 2004  ). The interference of 1,25(OH)  2 D 3  
with  the  Wnt –    -catenin pathway relies on the rapid induction of 
vitamin D receptor (VDR)  –      -catenin complexes that titrate out 
   -catenin, thus hampering formation of the transcriptional compe-
tent     -catenin  –  T cell factor (TCF) complexes that regulate genes 
involved in tumorigenesis (  P  á  lmer et al., 2001  ;   Shah et al., 2006  ). 
Linked to E-cadherin induction,     -catenin later relocates from the 
nucleus to the adherens junctions ( P á lmer et al., 2001 ). In contrast, 
the mechanisms leading to the induction of   CDH1 /E-cadherin  and 
the drastic reorganization of the cytoskeleton by 1,25(OH)  2 D 3  
remain unknown. 
 1,25(OH) 2 D 3   binds to and activates a member of the super-
family of nuclear receptors, the VDR, which is present in  > 30 cell 
types and acts as a ligand-modulated transcription factor regulat-
ing gene expression (genomic action). The current model for gene 
activation by 1,25(OH)  2 D 3  -VDR predicts that unliganded VDR 
bound to regulatory sequences (vitamin D response elements) in 
target genes represses their transcription by recruiting corepressors 
and histone deacetylases. 1,25(OH)  2 D 3   induces a conformational 
change in VDR that results in the replacement of corepressors by 
coactivators and an increased histone acetylase activity, which 
decondenses chromatin, thus allowing gene activation by the 
basal RNA polymerase II transcription machinery (  Sutton and 
MacDonald, 2003  ). 1,25(OH)  2 D 3   drastically alters the gene ex-
pression profi  le of many cell types: in human SW480-ADH colon 
carcinoma cells it regulates   >  200 genes involved in cell prolif-
  Figure 1.       1,25(OH)  2  D  3   activates the RhoA  –  ROCK pathway.   
(A) SW480-ADH cells were treated with 1,25(OH)  2  D  3   for the 
indicated times and RhoA activity was determined by GST 
pulldown. Normalized RhoAGTP levels are expressed as 
the mean   ±   SD (  n   = 3). (B) 1,25(OH)  2  D  3   does not modu-
late Rac or Cdc42. Levels of active Rac (RacGTP) and Cdc42 
(Cdc42GTP) were determined by GST pulldown in cells after 
1,25(OH)  2  D  3   addition. (C) Scheme of biochemical routes 
triggered by RhoAGTP and sites of inhibition by C3 exoen-
zyme and Y27632. (D) Cells were treated with 1,25(OH)  2  D  3   
for the indicated times and the level of phosphocoﬁ   lin 
(p-coﬁ  lin) and phospho-PRK2 (p-PRK2) were determined by WB. 
Normalized p-coﬁ  lin levels are expressed as the mean   ±   SD 
(  n   = 3). *, P   <   0.05; **, P   <   0.01; ***, P   <   0.001.     699 MECHANISM OF VITAMIN D ACTION IN COLON CANCER CELLS   • Ord  ó    ñ  ez-Mor  á  n et al. 
imaging, which was sustained as long as 1,25(OH)  2 D 3  was present 
(  Fig. 2 A  ). Removal of external Ca 
2+   abolished  this  increase, 
whereas its readdition induced a small Ca 
2+   overshoot (  Fig. 2 B  ). 
This fi  nding indicates that the effect was caused the mainte-
nance of Ca 
2+   entry rather than the transient release of Ca 
2+  
from intracellular stores. In SW480-R cells, derived from the 
same parental line as SW480-ADH but expressing very little 
VDR ( P á lmer et al., 2001 ), 1,25(OH)  2 D 3  induced a much lower, 
delayed [Ca 
2+ ] cyt   rise that was diffi  cult to distinguish from the 
gradual increase in [Ca 
2+ ] cyt   in vehicle-treated cells (  Fig. 2 C  ). 
The slight increase in [Ca 
2+ ] cyt   in SW480-R cell cultures was 
caused by only a few cells (  Fig. 2 C  ). Moreover, VDR knock-
down by means of small hairpin RNA (shRNA) abolished the 
increase in [Ca 
2+ ] cyt   (see   Fig. 8 C  ). These results indicate that 
VDR mediates Ca 
2+   infl  ux. However, although the presence of 
small amounts of VDR in caveolae has been postulated in 
some cell types (  Huhtakangas et al., 2004  ), we did not detect 
VDR at the plasma membrane by immunofl  uorescence. Fur-
thermore, incubation with an anti-VDR antibody did not 
Wennerberg, 2004  ), we examined their role in the phenotypic 
changes induced by 1,25(OH)  2 D 3   in SW480-ADH cells. 
1,25(OH)  2 D 3  caused a transient activation of RhoA, as measured 
by the increase in the level of RhoAGTP, but not of Rac or 
Cdc42, without affecting the RNA (unpublished data) or protein 
expression of any of these GTPases (  Fig. 1, A and B  ). Other 
hormones acting through nuclear receptors such as estrogen, 
retinoic acid, or dexamethasone had no effect on RhoA activity 
(unpublished data). 1,25(OH)  2 D 3  transiently increased the phos-
phorylation of cofi  lin, a downstream ROCK effector involved in 
cytoskeleton reorganization (  Maekawa et al., 1999  ), but not of 
protein-related kinase 2 (PRK2;   Fig. 1, C and D  ). 
  Next, we explored a possible link between activation of 
RhoA, which in some systems is Ca 
2+   dependent  ( Sakurada 
et al., 2003  ), and the 1,25(OH)  2 D 3  -induced changes in intra-
cellular Ca 
2+   levels reported in several cell types (  Losel and 
Wehling, 2003  ). The resting [Ca 
2+ ] cyt   was relatively high in 
SW480-ADH cells. 1,25(OH)  2 D 3   induced a marked increase 
in [Ca 
2+ ] cyt   as registered in individual cells by fl  uorescence 
  Figure 2.       1,25(OH)  2  D  3   induces Ca 
2+   inﬂ  ux in 
SW480-ADH cells.   (A) SW480-ADH cells were 
loaded with fura2/AM, perfused with external 
medium, and treated with 1,25(OH)  2  D  3   (4   ×   
10 
    7   M) or vehicle at the times indicated, and 
the [Ca 
2+  ]  cyt   was estimated by ﬂ  uorescence 
imaging. Records are mean   ±   SEM of 19  –  27 
cells representative of six independent experi-
ments. Insets show ﬂ  uorescence images coded 
in pseudocolor of fura2/AM-loaded SW480-
ADH cells before and after stimulation with 
1,25(OH)  2  D  3  . (B) Cells were incubated in nor-
mal or in Ca 
2+  -free medium and treated with 
1,25(OH)  2  D  3   as indicated. Data of [Ca 
2+  ]  cyt   
are the mean   ±   SEM of 19 cells representative 
of three independent experiments. (C) SW480-
ADH and SW480-R cells were incubated with 
1,25(OH)  2  D  3   or vehicle as indicated. The in-
crease in [Ca 
2+  ]  cyt   (right) corresponds to the 
maximum detected along the stimulation pe-
riod for 211 and 169 individual cells studied 
in six independent experiments for each cell 
type. The mean increase in untreated cells dur-
ing a similar period was subtracted. (D) IEC18 
cells were loaded with fura2/AM and treated 
with vehicle or 1,25(OH)  2  D  3   as indicated. Re-
cords are mean   ±   SEM of 33 and 28 cells, re-
spectively, representative of two independent 
experiments. (E) SW480-ADH cells were in-
cubated with 1,25(OH)  2  D  3  , lysophosphatidic 
acid (LPA), or the corresponding vehicle for 1 h 
in normal or in Ca 
2+  -free medium. Normalized 
RhoAGTP levels are expressed as the mean   ±   
SD (  n   = 3). (F) SW480-ADH cells were incu-
bated with 1   μ  M nimodipine (left) or 20   μ  M 
LaCl  3   (right) and then with 1,25(OH)  2  D  3   as 
indicated. Ca 
2+   measurements are mean   ±   
SEM of 24 cells representative of two inde-
pendent experiments. (G) Cells were prein-
cubated with 2   μ  g/ml actinomycin D (ActD; 
left) or 75   μ  M DRB (right) for 30 min before 
1,25(OH)  2  D  3   treatment. Ca 
2+   measurements 
are mean   ±   SEM of 30 cells representative of 
three independent experiments. (H) Cells were 
treated with ActD or DRB as in G, and with 
1,25(OH)  2  D  3   or vehicle for 1 h. Normalized 
RhoAGTP levels are expressed as the mean   ±   
SD (  n   = 3). **, P   <   0.01; ***, P   <   0.001.     JCB • VOLUME 183 • NUMBER 4 • 2008  700
  RhoA  –  ROCK activation mediates the 
induction of phenotypic change and 
E-cadherin expression by 1,25(OH)  2  D  3   
  To study the role of RhoA activation in 1,25(OH)  2 D 3   activity, we 
fi  rst used the C3 exoenzyme transferase, a Rho inhibitor (  Fig. 1 C  ). 
C3 exoenzyme altered the morphology of untreated cells and 
blocked the induction of an adhesive phenotype by 1,25(OH)  2 D 3  
(  Fig. 3 A  ). To confi  rm the involvement of RhoA in 1,25(OH)  2 D 3  
activity we generated SW480-ADH cells stably expressing the 
dominant-negative mutant N19-RhoA (Fig. S2, available at 
http://www.jcb.org/cgi/content/full/jcb.200803020/DC1). Expres-
sion of HA-tagged N19-RhoA did not affect posttranscriptional 
up-regulation of VDR by its ligand (  Wiese et al., 1992  ; Fig. S2). 
Likewise, it did not change the predominant nuclear localization 
of VDR (unpublished data). N19-RhoA cells showed a more 
rounded, less adherent phenotype than mock-transfected cells 
(  Fig. 3 C  ) and defects in cytokinesis that lead to polynucleated 
cells (  Glotzer, 2005  ;   Fig. 3 D  ). The induction of epithelioid islands 
by 1,25(OH)  2 D 3   was impaired in N19-RhoA cell cultures and it 
was also reduced by treatment with the ROCK inhibitor Y27632 
(  Fig. 1 C and Fig. 3 C  ). Immunofl  uorescence and confocal mi-
croscopy showed that 1,25(OH)  2 D 3  induced the progressive trans-
location of RhoA from the cytosol to the cell periphery and its 
colocalization with actin fi   laments in SW480-ADH cells 
( Fig.  3  D ).  Both expression of N19-RhoA and treatment with 
affect the increase in [Ca 
2+ ] cyt   (unpublished data). Remarkably, 
1,25(OH)  2 D 3   also increased [Ca 
2+ ] cyt   in the nontumoral rat in-
testine IEC18 cell line (  Fig. 2 D  ). We explored a possible as-
sociation between the effects of 1,25(OH)  2 D 3   on  [Ca 
2+ ] cyt   and 
RhoA. Incubation in Ca 
2+  -free medium abolished the activa-
tion of RhoA by its reported activator lysophosphatidic acid 
and also by 1,25(OH)  2 D 3  , indicating that Ca 
2+   infl  ux was re-
quired for RhoA activation (  Fig. 2 E  ). Nimodipine, an antago-
nist of the L-type voltage-gated Ca 
2+   channels, but not LaCl  3 , 
which blocks store-operated Ca 
2+   channels, prevented the in-
crease of [Ca 
2+ ] cyt   (  Fig. 2 F  ). Both Ca 
2+   infl  ux and RhoA acti-
vation are nongenomic 1,25(OH)  2 D 3   effects, as they were not 
affected by preincubation with the general transcription 
inhibitor actinomycin D or the RNA polymerase II inhibitor 
5,6-dichlorobenzimidazole riboside (DRB;   Fig. 2, G and H  ; 
and Fig. S1, available at http://www.jcb.org/cgi/content/full/
jcb.200803020/DC1). Although the relative abundance of re-
sponsive cells was larger at 1,25(OH)  2 D 3   doses of 4   ×   10 
   7   M 
than at 10 
   7   M (68   ±   8%,   n   = 157 cells studied in fi  ve indepen-
dent experiments, vs. 50   ±   12%,   n   = 101 cells studied in three 
independent experiments), no differences in the increase of 
[Ca 
2+ ] cyt   was found at the individual cell level (compare   Fig. 2 
[A and C]   with Fig. S1). The lack of effect of the glucocorti-
coid hormone dexamethasone on [Ca 
2+ ] cyt   supported the speci-
fi  city of 1,25(OH)  2 D 3   action (Fig. S1). 
  Figure 3.       RhoA  –  ROCK activation is neces-
sary for the induction of adhesive phenotype 
by 1,25(OH)  2  D  3  .   (A) Phase-contrast microscopy 
of cells pretreated with 2   μ  g/ml of C3 exo-
enzyme for 2 h and incubated with 1,25(OH) 2  D  3   
or vehicle for an additional 24 h. (B) Phase-
contrast microscopy of both SW480-ADH cells 
stably expressing exogenous mouse E-cadherin 
(SW480-ADH-E-cadherin) and SW480-R cells 
incubated with 1,25(OH)  2  D  3   or vehicle in the 
presence or absence of 10   μ  M Y27632 for 
48 h. (C) Phase-contrast micrographs of mock 
cells pretreated for 4 h with 10   μ  M Y27632 
or vehicle and of N19-RhoA cells upon incu-
bation with 1,25(OH)  2  D  3   or vehicle for 48 h. 
(D) Confocal laser microscopy images of mock 
and N19-RhoA cells treated as in C. Costain-
ing for the localization of RhoA (green) and 
F-actin (red). Merged images are also shown. 
All scanned, phase-contrast, and confocal mi-
croscopy images are representative of at least 
three independent experiments. Bars, 10   μ  m.     701 MECHANISM OF VITAMIN D ACTION IN COLON CANCER CELLS   • Ord  ó    ñ  ez-Mor  á  n et al. 
tion of E-cadherin by 1,25(OH)  2 D 3 .  Accordingly,  Y27632  and 
N19-RhoA inhibited the accumulation of E-cadherin protein at 
the adherens junctions after 1,25(OH)  2 D 3   treatment of SW480-
ADH cells (  Fig. 4 G  ). 
  RhoA  –  ROCK activation mediates the gene 
regulatory action of 1,25(OH)  2  D  3   
  We also analyzed the role of RhoA  –  ROCK in the effects of 
1,25(OH)  2 D 3   on other targets such as the   CYP24   gene.  As  for 
E-cadherin, each of the three agents, C3 exoenzyme, N19-RhoA, 
and Y27632, decreased the activation of the   CYP24   gene  pro-
moter by 1,25(OH)  2 D 3   in SW480-ADH and in SW480-R cells 
expressing exogenous VDR (  Fig. 5, A and B  ; unpublished data). 
Accordingly, N19-RhoA and Y27632 also decreased the accumu-
lation of   CYP24   RNA (  Fig. 5 C  ). Moreover, the induction of a 
series of 1,25(OH)  2 D 3   targets genes such as   osteopontin   ( OPN ), 
  osteocalcin   ( OCN  ), and   CYP3A   at the RNA level and integrin    3, 
ZO-1, DICKKOPF-1 (DKK-1), p21 
CIP1  , and paxillin at the pro-
tein  level  ( P á lmer  et  al.,  2001 ;   Ord ó  ñ ez-Mor á n  et  al.,  2005 ; 
 Aguilera et al., 2007 ) was blunted in N19-RhoA – expressing cells 
(  Fig. 5, D and E  ). N19-RhoA also inhibited the induction and ac-
cumulation of ZO-1 protein at the membrane where it colocalizes 
with cortical actin fi  laments (  Fig. 5 F  ). The same result was ob-
tained using Y27632 (unpublished data). Likewise, N19-RhoA 
and Y27632 inhibited the increase and redistribution of paxillin 
and the induction of focal contacts and stress fi  bers by 1,25(OH) 2 D 3  
as seen by immunofl  uorescence (Fig. S3, available at http://www
.jcb.org/cgi/content/full/jcb.200803020/DC1). Also in HT29 cells, 
Y27632 inhibited these 1,25(OH)  2 D 3   effects (  Fig. 3 D  ). Consis-
tent with the role of the RhoA – ROCK pathway in modulating the 
actin cytoskeleton (  Burridge and Wennerberg, 2004  ) and with the 
increase by 1,25(OH)  2 D 3  of actin-binding proteins ( P á lmer et al., 
2003 ),  1,25(OH) 2 D 3   induced (claudin-7) and redistributed (clau-
din-7 and occludin) tight junction proteins in a RhoA  –  ROCK  –
  dependent manner (Fig. S2). Y27632 partially disrupted the 
strong adhesive phenotype of cells stably expressing an exoge-
nous E-cadherin gene (SW480-ADH-E-cadherin) irrespective 
of 1,25(OH)  2 D 3   addition, whereas it did not alter the morphol-
ogy of E-cadherin and VDR-negative SW480-R cells that do not 
respond to 1,25(OH)  2 D 3   (  Fig. 3 B  ). In contrast, neither the C3 
exoenzyme nor Y27632 altered the level of E-cadherin ex-
pression in SW480-ADH-E-cadherin cells (Fig. S2). This fi  nd-
ing implicates ROCK in E-cadherin  –  dependent intercellular 
adhesion. Moreover, Y27632 also altered the adhesive pheno-
type and impeded 1,25(OH)  2 D 3   action in the more differenti-
ated HT29 colon carcinoma cells, in which RhoA was also 
activated by 1,25(OH)  2 D 3   as revealed by the increase in phos-
phocofi  lin (unpublished data). 
  Next we examined whether RhoA  –  ROCK controls E-
cadherin induction by 1,25(OH)  2 D 3  . The increase of E-cadherin 
RNA by 1,25(OH)  2 D 3   was reduced by C3 exoenzyme (  Fig. 4 A  ) 
in N19-RhoA cells (  Fig. 4 B  ) or by addition of Y27632 (  Fig. 
4 C  ). The same results were obtained when E-cadherin protein 
levels were analyzed (  Fig. 4, D and E  ) and on the activation of 
E-cadherin gene promoter (  Fig. 4 F  ). Collectively, these results 
indicate that RhoA  –  ROCK activation is required for the induc-
  Figure 4.       RhoA  –  ROCK activation is required 
for the induction of E-cadherin expression by 
1,25(OH)  2  D  3  .   (A) SW480-ADH cells were pre-
treated with 2   μ  g/ml of C3 exoenzyme or vehicle 
for 2 h before addition of 1,25(OH)  2  D  3   or vehicle 
(4 h), and the level of E-cadherin RNA was deter-
mined by qRT-PCR. (B) Mock and N19-RhoA cells 
were treated with 1,25(OH)  2  D  3   as indicated and 
the level of E-cadherin RNA was determined as 
in A. (C) SW480-ADH cells were pretreated or 
not with 10   μ  M Y27632 for 4 h and then with 
1,25(OH)  2  D  3   or vehicle for an additional 4 h, and 
the level of E-cadherin RNA was determined as in A. 
The data in A  –  C are expressed as the mean   ±   
SD (three independent experiments performed in 
triplicate). (D) SW480-ADH cells were pretreated 
with C3 exoenzyme (2 h) and then incubated with 
vehicle or 1,25(OH)  2  D  3   for an additional 20 h, 
and the level of E-cadherin protein was assessed 
by WB. Mean   ±   SD (  n   = 3). (E) Mock and N19-
RhoA cells were incubated with 1,25(OH)  2  D  3   
or vehicle (24 h) in the presence or absence of 
Y27632, and the expression of E-cadherin pro-
tein was assessed by WB. Mean   ±   SD (  n   = 3). 
(F) Mock and N19-RhoA cells were transiently trans-
fected with the plasmid encoding a fragment of the 
human E-cadherin gene promoter. After overnight 
incubation they were treated with Y27632 (4 h) 
and then incubated with 1,25(OH)  2  D  3   or vehicle 
(48 h). Mean   ±   SD (  n   = 3); r.l.u., relative luciferase 
units. (G) Confocal laser microscopy images show-
ing the immunolocalization of E-cadherin in mock 
cells pretreated or not with Y27632 (4 h) and in 
N19-RhoA cells incubated with 1,25(OH)  2  D  3   or 
vehicle (48 h). Bar, 10   μ  m. *, P   <   0.05; **, P   <   
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not repress the transcriptional activity of    -catenin – TCF  in  N19-
RhoA cells, whereas it weakly repressed that activity in Y27632-
treated mock cells ( Fig. 6 C ). These results show that RhoA – ROCK 
activation is required for the antagonism of the Wnt  –     -catenin 
pathway by 1,25(OH)  2 D 3  . In line with the effect of N19RhoA 
in other systems, N19RhoA cells grew less than mock cells 
(  Fig. 6 D  ). Additionally, the inhibitory effect of 1,25(OH)  2 D 3   on 
cell proliferation was lost in N19-RhoA cells (  Fig. 6 D  ). 
  p38MAPK and MSK1 are activated 
by 1,25(OH)  2  D  3   and mediate the induction 
of E-cadherin and   CYP24   gene 
  As several PKC isoforms respond to changes in Ca 
2+   levels, 
we studied the effects of PKC inhibitors on 1,25(OH)  2 D 3   ac-
tion (Fig. S4, available at http://www.jcb.org/cgi/content/full/
jcb.200803020/DC1). Ro318220, but not GF109203X, abrogated 
the increase of E-cadherin protein by 1,25(OH)  2 D 3   ( Fig.  7  A ). 
In addition, phosphorylation of PKD, a substrate of PKC, was 
decreased by GF109203X and Ro318220 but not affected by 
1,25(OH)  2 D 3   (  Fig. 7 A  ; unpublished data), thus implicating one 
or more Ro318220 target kinases other than the PKC family in 
E-cadherin induction. The candidates were MAPKAP-K1/RSK, 
Y27632 inhibited the increase of   CYP24   RNA, the induction of 
E-cadherin and vinculin proteins, and the decrease of cyclin D1 
by 1,25(OH)  2 D 3   (unpublished data). 
  RhoA  –  ROCK activation mediates the 
antagonism of the Wnt  –      -catenin pathway 
and the inhibition of cell proliferation 
by 1,25(OH)  2  D  3   
 1,25(OH) 2 D 3   induces the relocalization of     -catenin from the 
nucleus to the plasma membrane adherens junctions, where it 
binds E-cadherin, thus inhibiting the induction of proliferation 
and invasion genes by    -catenin – TCF  complexes  ( P á lmer  et  al., 
2001  ). Coimmunoprecipitation assays revealed that the forma-
tion of E-cadherin  –      -catenin complexes after 1,25(OH)  2 D 3   ad-
dition was decreased in N19-RhoA cells as compared with mock 
cells (  Fig. 6 A  ). Concordantly, the redistribution of    -catenin 
from the nucleus and cytosol to the plasma membrane induced 
by 1,25(OH)  2 D 3   was partially inhibited in N19-RhoA cells or 
by Y27632 (  Fig. 6 B  ). Likewise,     - and p120-catenins relocated 
at the plasma membrane after 1,25(OH)  2 D 3   addition and this 
effect was also diminished in N19-RhoA cells or by Y27632 
addition (  Fig. 6 B  ; unpublished data). Moreover, 1,25(OH)  2 D 3   did 
  Figure 5.       RhoA  –  ROCK mediates the induc-
tion of   CYP24   and other 1,25(OH)  2  D  3   target 
genes.   (A) SW480-ADH and -R cells were tran-
siently cotransfected with a plasmid encoding 
VDR and with a construct containing a frag-
ment of the human   CYP24   promoter-luciferase 
construct. After overnight incubation the cells 
were treated with 2   μ  g/ml of C3 exoenzyme 
for 2 h as indicated before addition (24 h) of 
1,25(OH)  2  D  3   or vehicle. (B) Mock and N19-
RhoA cells were transfected with the plasmid 
encoding a fragment of the human   CYP24   
promoter-luciferase construct. After overnight 
incubation they were treated with 1,25(OH)  2  D  3   
or vehicle for 6 or 9 h (left). Mock cells were 
similarly transfected and then incubated with 
1,25(OH)  2  D  3   or vehicle in the presence or 
absence of 10   μ  M Y27632 for 4 h (right). 
(C) Mock or N19-RhoA cells were incubated 
with 1,25(OH)  2  D  3   or vehicle (4 h) and the 
level of   CYP24   RNA was determined by qRT-
PCR (left). Mock cells were incubated with 
1,25(OH)  2  D  3   or vehicle in the presence or 
absence of 10   μ  M Y27632 for 4 h and the 
level of   CYP24   RNA was determined (right). 
(D) Mock or N19-RhoA SW480-ADH cells 
were incubated with 1,25(OH)  2  D  3   or vehicle 
for the indicated times and the expression of 
  OPN  ,   OCN  , and   CYP3A   RNA was determined 
by qRT-PCR. The data in A  –  D are expressed as 
the mean   ±   SD (three independent experiments 
performed in triplicate). (E) Mock or N19-
RhoA SW480-ADH cells were incubated with 
1,25(OH)  2  D  3   or vehicle for 4 (p21 
CIP1  ) or 48 h 
(all others), and the expression of integrin     3, 
ZO-1, DKK-1, paxillin, and p21 
CIP1   proteins 
were determined by WB. Controls:     -tubulin 
and -actin. The numbers below tracks represent 
the fold increase values in 1,25(OH)  2  D  3  -treated 
versus vehicle-treated cells. (F) Confocal laser 
microscopy images of mock and N19-RhoA 
cells incubated with 1,25(OH)  2  D  3   or vehicle 
(48 h) illustrating the localization of ZO-1 
(green) and F-actin (red). Bar, 10   μ  m. *, P   <   
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suggesting a role of p38MAPK-MSK1 in mediating 1,25(OH)  2 D 3  
action. Furthermore, Ro318220, H89, or SB203580 decreased the 
phosphorylation of histone H3, an MSK1 substrate (Fig. S4). The 
link between the activation of p38MAPK and MSK1 was further 
demonstrated by means of the p38MAPK activator anisomycin, 
which increased the level of phospho-MSK1 in an SB203580-, 
H89-, and Ro318220-sensitive manner (Fig. S4). 
 Consistent with these results, Ro318220, H89, or SB203580, 
but not GF109203X, Rp-cAMP, or U0126, prevented the induc-
tion of E-cadherin RNA (  Fig. 7 D  ). Ro318220 also blocked the 
activation of the E-cadherin gene promoter (  Fig. 7 E  ). More-
over, similar results were obtained with   CYP24   gene, except that 
U0126 and Rp-cAMP repressed the accumulation of its RNA 
(  Fig. 7 F  ) and PD98059 repressed the activation of the promoter 
by 1,25(OH)  2 D 3   (Fig. S4). Furthermore, in HT29 cells the in-
crease of   CYP24   RNA expression by 1,25(OH)  2 D 3   was inhibited 
by Ro318220 or SB203580 (unpublished data). These results im-
plicate p38MAPK-MSK1, MKK1-ERK, and PKA in the induc-
tion of   CYP24   by 1,25(OH)  2 D 3 . 
MSK1, PRK2, GSK-3    , and S6K1 (  Davies et al., 2000  ). S6K1 
was ruled out, as rapamycin, which specifi  cally inhibits its up-
stream regulator mTOR (  Davies et al., 2000  ), did not prevent 
the increase of E-cadherin protein by 1,25(OH)  2 D 3  (Fig. S4). PRK2 
was neither activated by 1,25(OH)  2 D 3   (  Fig. 1 D  ) nor affected by 
Ro318220 (Fig. S4). GSK-3     was ruled out as Ro318220 did 
not increase the level of Snail1 protein, a target of this kinase 
that accumulates upon GSK-3   blockade by LiCl in SW480-ADH 
cells (  Larriba et al., 2007  ; unpublished data). 
  We used additional inhibitors: H89, which inhibits PKA, 
MSK1, and S6K1 with similar IC  50   (  Davies et al., 2000  ), de-
creased E-cadherin induction; and Rp-cAMP, a specifi  c PKA 
inhibitor ( Davies et al., 2000 ), had no effect ( Fig. 7 B ). This ruled 
out PKA and pointed to MSK1. Because MSK1 is activated by 
either p38MAPK or MKK1  –  extracellular signal-regulated 
kinase (ERK;   Deak et al., 1998  ;   Dunn et al., 2005  ), we analyzed 
the effect of their respective inhibitors, SB203580 and U0126/
PD98059. SB203580, but not U0126 or PD98059, decreased 
the induction of E-cadherin protein ( Fig. 7 C ; unpublished data), 
  Figure 6.       RhoA  –  ROCK activation mediates the redistri-
bution of     -,     -, and p120-catenins and the inhibition of 
    -catenin  –  TCF transcriptional activity by 1,25(OH)  2  D  3  .   
(A) Mock and N19-RhoA cells were incubated with 
1,25(OH)  2  D  3   for the indicated times and the formation 
of complexes between E-cadherin and     -catenin was as-
sessed by coimmunoprecipitation (IP). Cell extracts were 
ﬁ  rst immunoprecipitated using an anti  –      -catenin antibody 
and the presence of E-cadherin and     -catenin (as control) 
in the immunoprecipitates was determined by WB. The IP 
was repeated four times with similar results. (B) Y27632 
and N19-RhoA inhibit the redistribution toward the plasma 
membrane compartment of     -,     -, and p120-catenins 
induced by 1,25(OH)  2  D  3  . Confocal laser microscopy im-
ages of mock (pretreated or not with 10   μ  M Y27632) and 
N19-RhoA cells incubated with 1,25(OH)  2  D  3   or vehicle for 
48 h.     -,     -, and p120-catenins were stained by immuno-
ﬂ  uorescence using speciﬁ  c antibodies and F-actin by phal-
loidin-rhodamine labeling, respectively. The images are 
representative of at least three independent experiments. 
Bar, 10   μ  m. (C) Mock and N19-RhoA SW480-ADH cells 
were transiently transfected with wild-type (TOP) or mutant 
(FOP) luciferase-base reporter plasmids for the transcrip-
tional activity of     -catenin  –  TCF complexes. After overnight 
incubation, the cells were treated with 1,25(OH)  2  D  3   or 
vehicle for 48 h in the presence or absence of 10   μ  M 
Y27632 and the intracellular luciferase activity was deter-
mined.     -catenin  –  TCF transcriptional activity (TOP/FOP 
ratio) is expressed as the mean   ±   SD (  n   = 3). (D) Mock 
and N19-RhoA cells were incubated with 1,25(OH)  2  D  3   or 
vehicle for the indicated times and the number of cells in 
the cultures was determined. The data represent one out 
of the four independent experiments performed in tripli-
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shRNA cells (  Fig. 8 B  ). In addition, VDR shRNA cells had a 
lower level of E-cadherin protein and showed no induction of 
  CYP24   promoter in the absence and particularly in the presence 
of 1,25(OH)  2 D 3   (  Fig. 8 B  ). Likewise, the induction of   CYP24 , 
  OPN ,   OCN  , and   CYP3A   RNA was blunted in VDR shRNA cells 
(unpublished data). Remarkably, 1,25(OH)  2 D 3   did not increase 
[Ca 
2+ ] cyt   (  Fig. 8 C  ) and did not activate RhoA (  Fig. 8 D  ), 
p38MAPK (  Fig. 8 E  ), or MSK1 (  Fig. 8 F  ) in VDR shRNA cells. 
Consistently, it did not increased CREB phosphorylation 
(  Fig. 8 F  ). Together, these results show that VDR is needed for 
the induction of the whole signaling pathway by 1,25(OH)  2 D 3 . 
  To know whether p38MAPK-MSK1 mediated the genomic 
effects of 1,25(OH)  2 D 3  in other cell types we used the SB203580 
and Ro318220 inhibitors. First, we checked that both agents in-
hibited effi  ciently the phosphorylation of CREB in nontumoral 
human HaCaT keratinocytes and IMR90 fi  broblasts, mouse 
NIH 3T3 fi  broblasts, and rat intestine IEC18 cells (Fig. S5, avail-
able at http://www.jcb.org/cgi/content/full/jcb.200803020/DC1). 
Next, the activation of   CYP24   promoter by 1,25(OH)  2 D 3   was 
found to be inhibited by Ro318220 or SB203580 in IEC18 and 
HaCaT and by Ro318220 and H89 in NIH 3T3 cells (Fig. S5). 
Finally, Ro318220 inhibited the induction by 1,25(OH)  2 D 3   of 
 We  confi  rmed that 1,25(OH)  2 D 3   increased the level of 
active, phosphorylated p38MAPK and MSK1 without affecting 
their total cellular content (  Fig. 7 G  ). Furthermore, 1,25(OH)  2 D 3  
increased phosphorylation of the transcription factors cAMP re-
sponse element-binding protein (CREB) and activating transcrip-
tion factor 1 (ATF1), which are MSK1 substrates (see   Fig. 9 B  ). 
Finally, the fi  nding that knockdown of MSK1 or MSK2 by siRNA 
decreased the induction of E-cadherin is further evidence that 
these kinases mediate 1,25(OH)  2 D 3   action (  Fig. 7 H  ). 
  The activation of the signaling pathway by 
1,25(OH)  2  D  3   requires VDR and takes place 
in other tumoral and nontumoral cell lines 
  To examine the dependence on VDR of the different components 
of the signaling pathway induced by 1,25(OH)  2 D 3 ,  we  knocked 
down VDR expression in SW480-ADH cells by means of infec-
tion with VDR shRNA lentiviruses. Two VDR shRNA (3 and 4) 
and one control shRNA cell lines were generated. Both VDR 
shRNA lines showed less intercellular adhesion and more rounded 
cells than control shRNA cells in both the absence and presence 
of 1,25(OH)  2 D 3   ( Fig.  8  A ).  We  confi  rmed that VDR shRNA 
cells expressed less basal and induced VDR protein than control 
  Figure 7.       p38MAPK and MSK1 mediate 
the induction of E-cadherin and   CYP24   by 
1,25(OH)  2  D  3  .   (A) SW480-ADH cells were 
pretreated with either vehicle, 3.5   μ  M 
GF109203X, or 2   μ  M Ro318220 for 2 h be-
fore incubation with 1,25(OH)  2  D  3   or vehicle 
for 20 h, and the level of E-cadherin protein 
and phosphoprotein kinase D (p-PKD) were 
determined by WB. Mean   ±   SD (  n   = 3). 
(B) Cells were pretreated with either vehicle, 
10   μ  M H89, or 20   μ  M Rp-cAMP for 2 h before 
incubation with 1,25(OH)  2  D  3   for 20 h and 
E-cadherin protein was determined by WB. 
Quantiﬁ   cation was as in A. (C) Cells were 
pretreated with either vehicle, 20   μ  M U0126, 
or 30   μ  M SB203580 for 2 h before incuba-
tion with 1,25(OH)  2  D  3   or vehicle for 20 h and 
E-cadherin protein and total and p-ERK1/2 
were determined by WB. Quantiﬁ  cation was 
as in A. (D) Cells were incubated (4 h) with 
1,25(OH)  2  D  3   or vehicle in the presence or ab-
sence of the indicated kinase inhibitor (same 
doses as in A  –  C) and E-cadherin RNA was 
determined by qRT-PCR (three independent ex-
periments performed in triplicate). (E) SW480-
ADH cells were transfected with the plasmid 
encoding a fragment of the human E-cadherin 
gene promoter. After overnight incubation 
they were treated (48 h) with 1,25(OH)  2  D  3   or 
vehicle in the presence or absence of 1   μ  M 
Ro318220. Mean   ±   SD (  n   = 3). (F) SW480-
ADH cells were incubated and treated as in 
D and the level of   CYP24   RNA was deter-
mined and quantiﬁ   cated as in D. (G) Cells 
were treated with 1,25(OH)  2  D  3   or vehicle and 
the expression of total and p-p38MAPK and 
p-MSK1 was determined by WB. Mean   ±   SD 
(  n   = 3). (H) SW480-ADH cells were transfected 
with MSK1 or MSK2 siRNA oligonucleotides or 
with scrambled oligos as control (C). 1 d later 
cells were treated with 1,25(OH)  2  D  3   or vehicle 
for an additional 6 h. E-cadherin, MSK1, and 
MSK2 protein levels were determined by WB. 
Mean   ±   SD (  n   = 3). *, P   <   0.05; **, P   <   0.01; 
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  Discussion 
  Natural and synthetic vitamin D compounds are increasingly 
studied as anticancer agents (  Deeb et al., 2007  ). Our results high-
light a signaling pathway triggered by 1,25(OH)  2 D 3   that starts 
with the Ca 
2+  infl  ux from the external medium and continues with 
the activation of RhoA – ROCK and then of the p38MAPK-MSK1 
kinase module. These are necessary steps for the regulation of 
gene expression, the antagonism of the Wnt  –     -catenin  pathway, 
and the induction of an adhesive epithelial phenotype (  Fig. 9 F  ). 
The Ca 
2+  infl   ux – RhoA – ROCK – p38MAPK-MSK1 pathway shown 
here links the nongenomic and genomic 1,25(OH)  2 D 3   effects  and 
demonstrates that the rapid modulation of ion content and cyto-
solic GTPases and kinases is required for the regulation of gene 
expression and cell physiology. 
  The activation of the nongenomic pathway requires VDR 
as shown by the generation and study of VDR shRNA cells and 
the analysis of VDR-defi  cient SW480-R cells. How these rapid 
and transcription-independent events are triggered is unclear, as 
we did not detect VDR at the plasma membrane and an anti-
VDR antibody failed to block Ca 
2+   infl  ux by 1,25(OH)  2 D 3 . These 
negative results do not rule out the presence of small amounts of 
VDR at the plasma membrane, as occurs with estrogen or pro-
gesterone nuclear receptors (  Losel et al., 2003  ;   Norman et al., 
2004 ). Moreover, the lack of effect on VDR knockdown by means 
of shRNA and in VDR-defi  cient SW480-R cells is consistent 
with the requirement of functional VDR in osteoblasts for the 
modulation of ion channel responses (  Zanello and Norman, 2004  ). 
  OPN  RNA in IMR90, HaCaT, and NIH 3T3 cells, that of  CYP3A  
RNA in IMR90 and HaCaT cells, and that of   CYP24   RNA  in  hu-
man Caco-2 colon and MCF-7 breast cancer cells (Fig. S5). 
  The activation of p38MAPK-MSK1 
is a downstream RhoA  –  ROCK event that 
is necessary for the interference of the 
Wnt  –      -catenin pathway by 1,25(OH)  2  D  3   
  Ro318220 did not prevent the rise in [Ca 
2+ ] cyt  , indicating that 
Ca 
2+   infl  ux is independent of MSK1 activation (  Fig. 9 A  ). Like-
wise, Ro318220 neither inhibited the increase in the level of 
RhoAGTP (unpublished data) or of phosphorylated cofi  lin by 
1,25(OH)  2 D 3   nor affected phospho-PRK2 (Fig. S4). The activa-
tion of p38MAPK and MSK1 by 1,25(OH)  2 D 3   was absent in 
N19-RhoA cells (  Fig. 9 B  ). In line with this, the level of phos-
phorylated CREB and ATF1 was increased by 1,25(OH)  2 D 3   in 
mock cells but did not change in N19-RhoA cells (  Fig. 9 B  ). 
Concordantly, pretreatment with Y27632 inhibited the increase 
of phosphorylated p38MAPK, MSK1, CREB, and ATF1 by 
1,25(OH)  2 D 3   in SW480-ADH cells (unpublished data). In addi-
tion, SB203580 or Ro318220 further reduced the induction of 
E-cadherin and   CYP24   RNA by 1,25(OH)  2 D 3   in N19-RhoA 
cells (  Fig. 9, C and D  ). Collectively, these results indicate that 
the p38MAPK-MSK1 module acts downstream of RhoA. 
  Finally, Ro318220 prevented the inhibition of the tran-
scriptional activity of   -catenin – TCF complexes by 1,25(OH) 2 D 3  
(  Fig. 9 E  ). This indicates that MSK1 also mediates the antago-
nism of the Wnt  –      -catenin pathway by 1,25(OH)  2 D 3 . 
  Figure 8.       VDR knockdown abrogates the 
induction of nongenomic signaling and gene 
expression by 1,25(OH)  2  D  3  .   (A) Phase-contrast 
images of SW480-ADH cells stably express-
ing control or VDR shRNA treated with 
1,25(OH)  2  D  3   or vehicle for 48 h as indicated. 
Bar, 10   μ  m. (B) Expression of VDR and E-
cadherin proteins (left) and   CYP24   promoter 
activity (right) in control and VDR shRNA cells that 
were treated or not with 1,25(OH)  2  D  3   for 24 h. 
Protein levels were determined by WB using 
    -actin as control and   CYP24   promoter activity 
was analyzed as in legend to   Fig. 5  . (C) Effect 
of VDR knockdown on the increase in [Ca 
2+  ]  cyt   
induced by 1,25(OH)  2  D  3  . The three cell types 
were loaded with fura2/AM and assessed for 
responsiveness to 1,25(OH)  2  D  3  . Traces are 
mean   ±   SEM values of control cells (black) 
or the two VDR shRNA lines (red and blue 
traces). Data are representative of at least two 
independent experiments for each cell line. 
(D) Control and VDR-4 shRNA cells were treated 
with 1,25(OH)  2  D  3   or vehicle for 1 h and RhoA 
activity was determined by GST pulldown. 
Normalized RhoAGTP levels are expressed as 
the mean   ±   SD (  n   = 3). (E) Control and VDR-4 
shRNA cells were treated with 1,25(OH)  2  D  3   
or vehicle for 2 h and the level of phospho- 
and total p38MAPK was determined by WB 
(mean   ±   SD,   n   = 3). (F) Control and VDR-4 
shRNA cells were treated with 1,25(OH)  2  D  3   
or vehicle for 2 h and the level of phospho-
MSK1 (p-MSK1) and phospho-CREB (p-CREB) 
in nuclear (N) and cytosolic (C) fractions was 
determined by WB. Total CREB and lamin B 
and     -tubulin were used as respective controls. 
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logue elocalcitol in human and rat bladder smooth muscle cells 
(  Morelli et al., 2008  ). Interestingly, the expression of the    1c  iso-
form of this channel is elevated in colon cancer as compared with 
adjacent normal mucosa (  Wang et al., 2000  ), which is compati-
ble with an effect of 1,25(OH)  2 D 3   in this neoplasia. 
 The role of RhoA in the induction of  CDH1 /E-cadherin and 
other target genes and the profound phenotypic change induced 
by 1,25(OH)  2 D 3   are consistent with its key function regulating 
the cytoskeleton, endocytosis, cell polarity, migration, gene tran-
scription, proliferation, differentiation, and oncogenesis (  Burridge 
and Wennerberg, 2004  ). The inhibitory effects of N19-RhoA and 
Y27632 on the induction and redistribution of tight junction and 
adherens junction proteins by 1,25(OH)  2 D 3   indicate that RhoA 
activation is crucial for the acquisition of polarity and the adhe-
sive phenotype, respectively, which are characteristics of differ-
entiated epithelial cells. Rho GTPases and E-cadherin function 
control each other: stable localization of E-cadherin at the adhe-
rens junctions requires Rho activity, whereas RhoA is inhibited 
VDR may not be the only receptor for 1,25(OH)  2 D 3  ( Nemere et al., 
2004 ).  However,  the  evidence from studies using cultured cells 
and genetically modifi  ed mice suggests that most 1,25(OH)  2 D 3   ac-
tions are mediated by VDR (  Erben et al., 2002  ). We conclude 
that the initial Ca 
2+  infl  ux is mediated by cytosolic VDR, although 
low membrane VDR levels as well as the binding of 1,25(OH)  2 D 3  
to a Ca 
2+   channel or an associated membrane protein cannot be 
ruled out. The conformational change induced by ligand bind-
ing in cytosolic VDR may trigger the initial signal, perhaps in-
directly by releasing putative associated factors. The cytosolic 
fraction of VDR has recently been localized in the vicinity of the 
plasma membrane in leukemia cells (  Gocek et al., 2007 ),  which 
would tend to support this hypothesis. Our fi  ndings imply a dual 
action of VDR, as a signaling molecule at the plasma membrane  –
  cytosol and as a transcription factor within the nucleus. 
  The use of antagonists indicates that L-type voltage-gated 
calcium channels mediate the Ca 
2+  infl  ux induced by 1,25(OH)  2 D 3 , 
as it has been recently reported in the case of the vitamin D ana-
  Figure 9.       p38MAPK-MSK1 activation by 1,25(OH)  2  D  3   depends 
on RhoA  –  ROCK and is necessary for the interference of the 
Wnt  –      -catenin pathway.   (A) SW480-ADH cells were incu-
bated with 1,25(OH)  2  D  3   in the presence of 2   μ  M Ro318220 
or vehicle. The [Ca 
2+  ]  cyt   was determined after 1,25(OH)  2  D  3   
addition. Mean   ±   SEM of 28  –  30 cells (three independent 
experiments). (B) Mock and N19-RhoA cells were incubated 
with 1,25(OH)  2  D  3   or vehicle (2 h) and the levels of total and 
phospho-p38MAPK, -MSK1, -CREB, and -ATF1 were deter-
mined by WB. Mean   ±   SD (  n   = 3). (C) Mock and N19-RhoA 
cells were pretreated with vehicle, 30   μ  M Ro318220, or 30   μ  M 
SB203580 (2 h) and then incubated with 1,25(OH)  2  D  3   for 
additional 4 h, and the level of E-cadherin RNA was deter-
mined by qRT-PCR. Mean   ±   SD (three independent experi-
ments performed in triplicate). (D) Mock and N19-RhoA cells 
were incubated (4 h) with 1,25(OH)  2  D  3   in the presence of ve-
hicle, Ro318220, or SB203580, and the level of   CYP24   RNA 
and quantiﬁ  cation was determined as in C. (E) SW480-ADH 
cells were transfected with wild-type (TOP) or mutant (FOP) 
reporter plasmids for     -catenin  –  TCF activity. After overnight 
incubation, the cells were treated (48 h) with either vehicle or 
1,25(OH)  2  D  3   in the presence or absence of 1   μ  M Ro318220. 
Mean   ±   SD (  n   = 3). (F) Scheme of the mechanism of action 
of 1,25(OH)  2  D  3   in human SW480-ADH cells. A rapid, VDR-
dependent nongenomic signaling pathway that starts with 
Ca 
2+   inﬂ   ux and continues with the sequential activation of 
RhoA GTPase and the kinases ROCK, p38MAPK, and MSK1 
converges in the nucleus with ligand-activated VDR to regu-
late gene expression and interfere with the Wnt  –      -catenin 
pathway leading to proliferation arrest and epithelial differen-
tiation. MSK1 may target VDR and/or its coregulators and/or 
downstream transcription factors. *, P   <   0.05; **, P   <   0.01; 
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Velde, Solvay, Weesp, Netherlands) were performed in DME supplemented 
with charcoal-treated serum. To ensure dose dependence, 1,25(OH)  2  D  3   was 
used in the range 10 
    9   to 10 
    7   M; data shown correspond to 10 
    7   M un-
less speciﬁ  ed (see Calcium imaging section). Cells were transfected using 
the jetPEI reagent (PolyPlus Transfection), achieving an efﬁ  ciency of 60% 
as judged by ﬂ  uorescence. In transient transfections,   Fireﬂ  y   (Luc) and   Re-
nilla reniformis   luciferase (Rluc) activities were measured separately using 
the Dual Luciferase reagent kit (Promega) and a Lumat LB9507 luminome-
ter (Berthold). Luc activity was normalized to the Rluc activity. The human 
  CYP24   promoter (    367/+1 fragment containing two vitamin D response 
elements at     293/    273 and     172/    143 positions), luciferase reporter, 
and VDR expression plasmids were a gift from A. Aranda (Instituto de In-
vestigaciones Biom  é  dicas, Madrid, Spain); and the RhoA constructs were 
obtained from P. Crespo (Instituto de Biomedicina y Biotecnolog  í  a de 
Cantabria, Santander, Spain). The   CDH1  /E-cadherin promoter activity was 
studied using the     987-TK-Luc construct (  P  á  lmer et al., 2001  ). To study 
    -catenin  –  TCF transcriptional activity we used the TOP-Flash and FOP-Flash 
plasmids containing multimerized wild-type (CCTTTGATC) or mutated 
(CCTTTGGCC) TCF/LEF-1 binding sites upstream of a minimal c-  fos   pro-
moter driving luciferase gene expression (  Korinek et al., 1997  ; a gift from 
H. Clevers, Hubrecht Institute and University Medical Center, Utrecht, Neth-
erlands). Mock and N19-RhoA cells were generated by stable transfection 
of SW480-ADH cells with HA-tagged empty vector or N19-RhoA cDNA 
and selection with 0.3 mg/ml G418 (Sigma-Aldrich). 
  Gene silencing 
  To knock down VDR expression, SW480-ADH cells were infected with len-
tiviral particles containing a U6 promoter driven by an shRNA targeting 
VDR. These constructs belong to the MISSION TRC-Hs 1.0 shRNA library 
(Sigma-Aldrich). Infected cells were selected with puromycin at 1   μ  g/ml. 
Control cells were infected with lentivirus bearing a nontargeting shRNA 
that activates the RISC complex and the RNA interference pathway but that 
contains at least ﬁ  ve mismatched nucleotides compared with any human 
gene (clone SHC002; Sigma-Aldrich). MSK1 and MSK2 siRNA oligonucle-
otides (siGENOME SMART pool MSK1 and MSK2; Thermo Fisher Scien-
tiﬁ  c) and control oligonucleotides (siControl nontargeting siRNA pool #1; 
Thermo Fisher Scientiﬁ   c) were transfected using Lipofectamine 2000 in 
OPTIMEM medium (both from Invitrogen). Transfection efﬁ  ciency  was 
judged to be   >  90% using ﬂ  uorescent-labeled oligonucleotides. 
  Inhibitors 
  The inhibitor C3 exoenzyme (Rho) was obtained from Cytoskeleton, Inc.; 
Ro318220 (PKC, MSK, p70S6K1, PRK2, GSK-3    , and p90S6K1/RSK1), 
SB203580 (p38MAPK), GF109203X (PKC), Y27632 (ROCK), H89 (PKA, 
MSK1, and S6K1), Rp-cAMP (PKA speciﬁ  c), PD98059 and U0126 (MKK1), 
and rapamycin (mTOR-S6K1) were obtained from EMD. The potency and 
speciﬁ  city of these kinase inhibitors have been reported elsewhere (  Davies 
et al., 2000  ). The transcription inhibitors actinomycin D and DRB, the 
p38MAPK activator anisomycin, and lysophosphatidic acid were obtained 
from Sigma-Aldrich. Nimodipine and LaCl  3   were obtained from Bayer AG 
and Sigma-Aldrich, respectively. 
  Antibodies 
  We used primary mouse monoclonal antibodies against RhoA and phos-
pho-ERK1/2 (Santa Cruz Biotechnology, Inc.); Cdc42, Rac, E-cadherin, 
    - and p120-catenin, PRK2, and paxillin (BD); integrin     3 (Millipore); 
    -tubulin (Sigma-Aldrich); p21 
  CIP  1   (Millipore); HA (Babco); rat monoclonal 
antibodies against VDR (Millipore) and MSK2 (R  &  D Systems); rabbit 
polyclonal antibodies against RhoA, cyclin D1, and ERK2 (Santa Cruz Bio-
technology, Inc.);     -catenin (Sigma-Aldrich); total and phosphocoﬁ  lin, phospho-
p38MAPK, -S6K1, -CREB (Ser 
133  )/ATF1, -MSK1 (Ser 
581  ), -PRK2, -histone H3 
(Ser 
10  ), and -PKD (Cell Signaling Technology); occludin, ZO-1, and claudin-7 
(Invitrogen); and goat polyclonal antibodies against     -actin, lamin B, MSK1, 
and DKK-1 (Santa Cruz Biotechnology, Inc.). 
  RNA synthesis 
  30,000 cells were seeded in 24-well dishes. After overnight incubation, 
cells were pulsed with 1   μ  Ci/ml [5- 
3  H]uridine 5    -triphosphate (Hartmann 
Analytic) for 4 h in the presence of the indicated doses of actinomycin D or 
vehicle (added 30 min before). At the end of the labeling period, the me-
dium was removed and the cells were rinsed twice in PBS and ﬁ  xed with 
chilled 10% trichloroacetic acid for 10 min. Trichloroacetic acid was then 
removed and the monolayers were washed in ethanol and air dried at 
room temperature for 20 min. Thereafter, precipitated macromolecules 
were dissolved in 500   μ  l of 0.5 N NaOH-0.1% SDS and 450   μ  l of each sam-
ple was diluted in 5 ml of scintillation solution OptiPhase HiSafe (PerkinElmer). 
by E-cadherin ( Braga et al., 1997 ,  1999 ;  Noren et al., 2001 ;  Braga 
and Yap, 2005  ;   Reynolds, 2007  ). The effect of 1,25(OH)  2 D 3   on 
RhoA is transient. The rapid activation of RhoA may be a re-
sponse to the increase in [Ca 
2+ ] cyt  , whereas the down-regulation 
may be a consequence of the later accumulation of E-cadherin 
and p120-catenin at the plasma membrane, as E-cadherin acti-
vates and p120-catenin recruits the Rho inhibitor p190RhoGAP 
(  Noren et al., 2001  ,   2003 ;   Wildenberg  et  al.,  2006 ).  This  tran-
sient nature of RhoA activation is probably crucial, as we were 
unable to generate SW480-ADH cells stably expressing consti-
tutively active RhoA caused by cytotoxicity. 
 MSK1, the downstream kinase activated, is predominantly 
nuclear, although its presence in the cytosol has also been docu-
mented, and it participates in the nucleosome response associ-
ated with immediate-early gene induction ( Thomson et al., 1999 ). 
MSK1 may phosphorylate VDR and/or its coregulators or com-
ponents of any of the multiprotein complexes (DRIP-TRAP and 
Mediator) involved in transcriptional control by 1,25(OH)  2 D 3 -
VDR. Perhaps a more plausible role of MSK1 may be the regu-
lation of downstream transcription factors: MSK1 may recruit 
coactivators or promote interactions with chromatin-modifying 
or -remodeling complexes through its ability to phosphorylate 
transcription factors such as CREB or ATF1 or the histone H3 
tail (  Dunn et al., 2005  ). Recently, ERK activation by progestins 
has been reported to cause progesterone receptor phosphoryla-
tion and MSK1 activation, which is followed by recruitment of 
a complex of the three proteins to a nucleosome on the mouse 
mammary tumor virus promoter and its subsequent induction 
(  Vicent et al., 2006  ). Putatively, MSK1 (and possibly the 75% 
homologous MSK2, according to the knockdown experiments) 
plays similar roles in gene activation by 1,25(OH)  2 D 3  . In the case 
of E-cadherin it depends on p38MAPK-MSK1 activation, but 
in the case of   CYP24   it also depends on MKK1-ERK and PKA. 
Additionally, the fi  nding that the antagonism of the Wnt –   -catenin 
pathway by 1,25(OH)  2 D 3  , which is mediated by VDR  –     -catenin 
interaction (  P  á  lmer et al., 2001  ;   Shah et al., 2006  ), is sensitive to 
Ro318220 points to effects of MSK1 at the VDR level. 
  Our results raise interesting questions such as the role of 
nuclear versus cytosolic VDR, how Ca 
2+   can activate RhoA, or 
which are the MSK1 substrates relevant for 1,25(OH)  2 D 3   action. 
These questions and whether the Ca 
2+   infl   ux – RhoA – ROCK –
  p38MAPK-MSK1 pathway is responsible for or participates in 
1,25(OH)  2 D 3   action in other cellular processes will require fur-
ther work. The identifi  cation of this route as crucial for the con-
trol of human colon carcinoma cell proliferation and phenotype 
opens novel possibilities of pharmaceutical intervention for the 
second most lethal neoplasia worldwide (  Jemal et al., 2006  ). 
  Materials and methods 
  Cell culture and transfections 
  Tumoral human SW480-ADH and SW480-R cells (derived from the 
SW480 cell line by limit dilution [  P  á  lmer et al., 2001  ]), HT29, Caco-2 (co-
lon) and MCF-7 (breast) cells, and nontumoral human IMR90 (ﬁ  broblasts) 
and HaCaT (keratinocytes), rat IEC18 (intestine), and mouse NIH 3T3 (ﬁ  -
broblasts) cells were cultured in DME plus 10% fetal bovine serum (Invitro-
gen). SW480-ADH-E-cadherin cells were previously described (  Aguilera 
et al., 2007  ). All experiments using 1,25(OH)  2  D  3   (provided by R. Bouillon 
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samples were obtained at 20  °  C with a laser-scanning confocal microscope 
(LSM 510; Carl Zeiss, Inc.) using plan apochromat immersion oil 63x NA 
1.4 objective lens and argon ion (488 nm) and HeNe (543 nm) lasers. 
Images were acquired sequentially by direct register using LSM software 
(Carl Zeiss, Inc.) without manipulation; for double labeling experiments, 
images of the same confocal plane were generated and superimposed. 
Phase-contrast images were captured with a digital camera (DC300; Leica) 
mounted on an inverted microscope (Labovert FS; Leitz). TIFF images were 
processed using Photoshop 7.0 software (Adobe). 
  Quantitative RT-PCR (qRT-PCR) 
  Total RNA was puriﬁ  ed using RNeasy mini kits following the manufacturer  ’  s 
instructions (QIAGEN). To measure the RNA levels for   CDH1  /E-cadherin, 
  OPN, OCN, CYP3A  , and   GAPDH  , we used oligonucleotides (5    -AGAAC-
GCATTGCCACATACACTC-3     and 5    -CATTCTGATCGGTTACCGTGATC-3     
for   CDH1  /E-cadherin; 5    -TTGCAGTGATTTGCTTTTGC-3     and 5    -GTCATG-
GCTTTCGTTGGACT-3     for  OPN  ; 5   -GCACAGCCCAGAGGGTATAA-3     and 
5    -CGCCTGGGTCTCTTCACTAC-3     for   OCN  ; 5    -GATGAAAGAAAGTC-
GCCTCG-3     and 5    -TGCAGTTTCTGCTGGACATC-3     for   CYP3A  ; 5    -AC  A-
GT  CCATGCCATCACTGCC-3     and 5    -CTAGCTGACCTCCTTGACCTG-3     
for   GAPDH  ) and SYBR green, and for   CYP24   and   18S   rRNA, we used 
TaqMan probes (Applied Biosystems) with a 7900HT fast real-time PCR 
system (Applied Biosystems). The PCR cycling conditions used were as 
follows: incubation at 95  °  C for 10 min followed by 40 cycles of 15 s at 
95  °  C, 60 s at 60  °  C, and 5 s at 72  °  C. At the end of the PCR cycles, melting 
curve analyses were performed, and the extent of induction was calculated 
as described previously (  Perakyla et al., 2005  ). 
  Statistical analysis 
  The data are expressed as the mean   ±   SD unless otherwise speciﬁ  ed. Statisti-
cal signiﬁ  cance was assessed by two-tailed unpaired student  ’  s   t   test. The single 
asterisk indicates P   <   0.05, the double asterisk P   <   0.01, and the triple asterisk 
P   <   0.001. When P   >   0.05, the data were considered not signiﬁ  cant. All sta-
tistical analyses were performed using Instat 3.0 software (GraphPad). 
  Online supplemental material 
  Fig. S1 shows controls for transcription inhibition by actinomycin D and 
DRB in SW480-ADH cells and the speciﬁ  city of the increase of [Ca 
2+  ]  cyt   by 
10 
    7   M 1,25(OH)  2  D  3  . Fig. S2 shows the lack of effect of N19-RhoA on VDR 
expression in SW480-ADH cells and of C3 exoenzyme and Y27632 on 
E-cadherin expression in SW480-ADH-E-cadherin cells and the dependence 
on RhoA  –  ROCK of the induction of claudin-7 and occludin by 1,25(OH)  2  D  3  . 
Fig. S3 shows the inhibition by N19-RhoA and Y27632 of the induction of 
paxillin, stress ﬁ  bers, and focal contacts by 1,25(OH)  2  D  3  . Fig. S4 shows 
a scheme of the action of the kinase inhibitors used, their effect on cell 
viability, on E-cadherin expression and S6K1 phosphorylation (rapamycin), 
on histone H3 (GF109203X, Ro318220, SB203580, H89, and Rp-cAMP), 
on MSK (H89, Ro318220, and SB203580), and on coﬁ  lin and PRK2 phos-
phorylation (Ro318220). Additionally, it shows the effect of PD98059 on 
  CYP24   promoter activation induced by 1,25(OH)  2  D  3  . Fig. S5 shows the in-
hibitory effect of Ro318220 and SB203580 on the induction of CREB phos-
phorylation, the activation of   CYP24  ,   OPN  , and   CYP3A   promoters, and the 
increase of   CYP24   RNA levels by 1,25(OH)  2  D  3   in a panel of normal and tu-
moral cell lines of human and rodent origin. Online supplemental material is 
available at http://www.jcb.org/cgi/content/full/jcb.200803020/DC1. 
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